What Is NAD+?

1. How does NAD+ work?

During the breakdown of nutrients, NAD+ accepts electrons and becomes NADH. NADH can then supply electrons to reactions that help produce ATP, the molecule cells use to power work. NAD+ and NADH continually cycle between these states. Increasing the size of that pool does not automatically increase how much energy a person produces or feels.

Other enzymes consume NAD+ during their work. These include PARPs, involved in responses to DNA damage, and sirtuins, which help regulate proteins involved in metabolism and stress responses. CD38 also breaks down NAD+ and participates in cellular signaling. The NAD+ infusion study by Grant and colleagues describes these roles and the molecule’s metabolism.

Cells replenish NAD+ through several pathways, including recycling nicotinamide. Calling NAD+ a peptide is a chemical error: peptides consist of amino acids, whereas NAD+ consists of linked nucleotides. Its appearance beside MOTS-c in a product catalog does not give the two compounds the same mechanism.

2. NAD+ vs NMN vs NR: what are you buying?

“NAD+ supplement” can describe several different ingredients. Read the ingredient name before comparing doses or study results.

In Christen and colleagues’ 2026 comparison, 67 healthy adults were randomized and 65 entered the main analysis. After 14 days, 1,000 mg/day of either NR or NMN roughly doubled baseline whole-blood NAD+; 500 mg/day of nicotinamide did not. The trial was open-label, measured metabolism rather than performance or longevity, and included authors employed by Nestlé.

Those results support both precursors as ways to change a blood measurement. They do not establish that NMN is better because it sits closer to NAD+ in a pathway, or that NR is better for every goal. A capsule labeled “liposomal” also needs evidence for its particular formulation; the label alone supplies no measured advantage in bioavailability.

3. NAD+ benefits: what have human trials found?

The studies below answer different questions. Doses describe research protocols, not recommendations. A positive result in a disease population cannot predict the same gain in a healthy athlete.

Energy, endurance and recovery

The Liao runner trial is relevant to people who train. Participants exercised five or six times a week. The medium- and high-dose groups improved some measures at ventilatory thresholds, points at which breathing changes as effort rises. Researchers found no improvement in VO₂ max or peak power. With only 12 people per group, the experiment offers a reason for replication rather than a dependable race-time prediction.

The NICE trial found a functional benefit in people whose leg circulation limited walking. At six months, six-minute walking distance changed by +7.0 m with NR and −10.6 m with placebo. The 17.6 m difference reflects both changes. The trial used a prespecified one-sided analysis and a 90% confidence interval; it was preliminary evidence in peripheral artery disease. Adding resveratrol did not enhance the result.

Neither trial establishes faster recovery from lifting, higher daily energy in healthy users or a benefit from an NAD+ drip.

Glucose control and fat loss

In the Yoshino trial, muscle insulin sensitivity improved by about 25% after NMN. Researchers measured how well insulin promoted glucose disposal under controlled conditions. Participants did not lose body fat, and fasting glucose did not improve.

The Dollerup trial found no metabolic benefit from a much larger daily amount of NR in men with obesity and insulin resistance. The different molecule and population prevent a clean dose comparison. Together, the studies give little support to treating “NAD+ boosting” as a predictable fat-loss strategy.

Memory and focus

The 2026 Martens pilot separates a biochemical response from a cognitive one. Among 42 completers, NR doubled blood NAD+ without improving cognition over 12 weeks. Exploratory regional brain-blood-flow findings need follow-up; the primary outcome was negative. This study involved cognitive impairment and cannot determine every possible effect in healthy adults, but it provides no basis for promising better focus from a higher NAD+ reading.

4. Does NAD+ decline with age, and can replacing it slow aging?

Some human measurements support an age-related decline. Zhu and colleagues’ 2015 brain study used magnetic resonance spectroscopy to measure NAD+ and NADH in living people. Older age was associated with lower brain NAD+ and a different NAD+/NADH balance.

That finding cannot supply a universal percentage lost by age 40 or 50. Tissue, measurement method and population affect the answer. It also cannot establish that increasing a blood value restores a younger brain or prevents age-related disease. An association identifies a research question; a treatment trial must show whether changing it helps.

A 2026 systematic review by Gallagher and Emmanuel identified 33 human intervention studies through October 2025. Oral precursors commonly changed NAD-related measurements, while health and functional outcomes were inconsistent or specific to particular endpoints. The review found clinical effectiveness for anti-aging and wellness inconclusive. Later studies described above add information, without establishing human lifespan extension.

A biological-age score or blood NAD+ result is a surrogate measurement. To establish longer healthspan, researchers need outcomes such as sustained physical function, less disease or fewer years with disability, measured over adequate follow-up.

5. NAD+ IV therapy and injections: what does the evidence show?

An IV puts material into the bloodstream. It does not establish how much intact NAD+ reaches a muscle cell’s mitochondria, or whether that exposure improves health.

In Grant and colleagues’ 2019 pilot, eight men received 750 mg NAD+ over six hours and three received saline. Researchers followed plasma and urine metabolites. The study did not test improved cognition, athletic performance or lifespan. It also did not validate a subcutaneous injection schedule.

Newer research includes a 2026 retrospective study by Reyna and colleagues. Commercial clinic records showed more troublesome infusion symptoms with NAD+ than with IV NR, including gastrointestinal symptoms, increased heart rate and chest pressure. NAD+ infusions took longer on average. This was a small, nonrandomized comparison with commercial affiliations and 30-day follow-up, rather than a placebo-controlled test of wellness benefits.

Oral NR, intravenous NR and intravenous NAD+ are three different interventions. Findings for one cannot establish the effects of another. The same requirement applies to subcutaneous, intramuscular, nasal and sublingual products. Claims that a route is “100% bioavailable” leave clinical benefit unanswered even if delivery to blood is complete.

6. NAD+ dosage, half-life and cycling

There is no validated NAD+ wellness regimen that establishes a loading phase, maintenance injection or cycling schedule for longevity. The table above shows how widely oral precursor studies differ in dose, duration and participants. Copying the largest dose would ignore trials that found no benefit at that exposure.

A useful half-life estimate must specify the molecule, route and compartment measured. NAD+ in plasma, NAD+ inside blood cells and a precursor’s breakdown products are different measurements. None directly supplies the duration of a perceived energy effect.

The six-hour infusion pilot cannot tell someone how often to inject NAD+ under the skin. Nor does a two-week rise during daily oral supplementation establish how long that rise persists after stopping. A calculator can draw a curve from an assumed half-life, but it cannot validate the assumption or convert it into an evidence-based schedule.

7. NAD+ side effects and injectable quality

Short oral trials provide some reassurance about tolerability under their study conditions. In the 12-week Dollerup trial, investigators reported no serious adverse events attributed to NR and normal safety blood tests. That cannot exclude uncommon harms or establish safety over years, during pregnancy or in populations excluded from the trial.

Injectables add manufacturing concerns. The FDA warns about compounders using food-grade NAD+ for sterile products. Food-grade material is unsuitable without appropriate processing because microbes and endotoxins can contaminate it. FDA received reports of severe chills, shaking, vomiting and fatigue, sometimes requiring medical treatment; those reactions were consistent with excessive endotoxin levels.

A purity percentage on raw powder does not establish sterility or acceptable endotoxin levels in a finished injection. Infusion discomfort also provides no evidence that cellular repair is occurring. New chest pressure or severe systemic symptoms during an infusion warrant immediate attention from the treating clinician.

8. NAD+ blood tests and combinations with other compounds

Before interpreting a before-and-after result, identify what the laboratory measured: whole-blood NAD+, plasma NAD+, NADH, a ratio or a breakdown product. Comparisons become difficult when the sample type, assay or timing relative to supplementation changes. Blood measurements also cannot establish the concentration in brain or muscle.

The Yoshino study illustrates the problem. Blood-cell NAD+ increased, but measured muscle NAD+ did not, despite improved muscle insulin sensitivity. A single blood marker cannot describe every tissue response. The trials discussed here do not validate a universal “optimal NAD+” target for healthy people.

Combining NAD+ products with tirzepatide, semaglutide or MOTS-c requires evidence for the combination. The cited trials do not establish that these stacks prevent muscle loss, treat GLP-1-related fatigue or improve fat loss. A plausible metabolic explanation cannot quantify added benefit or interactions.

For personal records, keep the exact ingredient, route, dates and symptoms separate from the outcome you care about. Training pace, workload and sleep context answer different questions from a blood NAD+ test. If you change several supplements and your training plan together, the record cannot identify which change caused the result. The tracking guide covers ways to keep those records consistent; a personal log remains an observation, with the same limits on cause and effect.

9. NAD+ FAQ

• What is NAD+ used for?

  Cells use NAD+ in energy metabolism and enzymes involved in repair and signaling. Supplements and infusions are marketed for energy, recovery and longevity, but those uses have uneven clinical evidence. The body's need for NAD+ does not establish a benefit from taking extra.

• Is NAD+ a peptide?

  No. NAD+ is nicotinamide adenine dinucleotide, a coenzyme made from two linked nucleotides. It appears in supplement and peptide catalogs, but it is chemically different from amino-acid chains such as MOTS-c.

• Is NMN or NR better than NAD+?

  NR and NMN have more randomized human research as oral supplements than NAD+ itself has as a wellness infusion. Both can raise measured blood NAD+. Trials have not established a universal winner for longevity, energy or cognition. Results depend on the product, route, population and outcome.

• Does NAD+ reverse aging?

  Human research has not established that NAD+ infusions or oral precursors reverse aging or extend lifespan. Short-term changes in blood NAD+ or an aging-related biomarker cannot demonstrate fewer years of disability or longer survival.

• How much NAD+ should you take?

  There is no validated NAD+ dose or injection cycle for general longevity or performance. Oral NR and NMN trial doses are research exposures, not interchangeable prescriptions for NAD+ injections. More milligrams do not reliably mean more benefit.

• How long does NAD+ last?

  There is no single duration covering blood NAD+, intracellular NAD+, precursors and a perceived energy effect. Infusion measurements cannot establish how often someone should receive a subcutaneous injection or how long a wellness benefit lasts.

• Can NAD+ help with weight loss or GLP-1 fatigue?

  NAD+ products have no established role as weight-loss treatments or as a remedy for fatigue during semaglutide or tirzepatide treatment. Improved insulin sensitivity in a small NMN trial did not come with reduced body fat. Combination benefits need their own controlled studies.

• Are NAD+ injections safe?

  Small studies cannot establish long-term safety. Infusion symptoms have included gastrointestinal distress, increased heart rate and chest pressure. Separately, FDA reports severe chills, shaking, vomiting and fatigue after injectable NAD+ products, consistent with excessive endotoxin levels.

10. Sources